Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $100,723 | $73,042 | $127,348 | $154,192 |
| - Cash | $42,184 | $64,676 | $104,253 | $120,572 |
| + Debt | $55,992 | $95,894 | $112,514 | $110,358 |
| Enterprise Value | $114,531 | $104,260 | $135,609 | $143,978 |
| Revenue | $8,541 | $8,056 | $7,679 | $7,190 |
| % Growth | 6% | 4.9% | 6.8% | – |
| Gross Profit | $7,827 | $7,181 | $6,792 | $6,178 |
| % Margin | 91.6% | 89.1% | 88.4% | 85.9% |
| EBITDA | -$21,080 | -$31,071 | -$34,192 | -$37,346 |
| % Margin | -246.8% | -385.7% | -445.3% | -519.4% |
| Net Income | -$24,225 | -$35,828 | -$38,669 | -$41,769 |
| % Margin | -283.6% | -444.7% | -503.6% | -580.9% |
| EPS Diluted | -0.42 | -0.63 | -0.68 | -0.74 |
| % Growth | 33.3% | 7.4% | 8.1% | – |
| Operating Cash Flow | -$19,453 | -$30,841 | -$37,461 | -$26,992 |
| Capital Expenditures | -$1,114 | -$38 | $0 | -$34 |
| Free Cash Flow | -$20,567 | -$30,879 | -$37,461 | -$27,026 |